Web20 mag 2013 · Request PDF A phase I/II study of biweekly docetaxel (D) in combination with fixed-dose cisplatin plus fluorouracil (CF) in patients (pts) with advanced esophageal cancer (AEC) (JCOG0807 ... http://www.jcog.jp/document/s_0807.pdf
Did you know?
Web1 lug 2014 · cancer (JCOG0807) Shuichi Hironaka, 1 Yasuhiro Tsubosa, 2 Junki Mizusawa, 3 Takayuki Kii, 4 Ken Kato, 5 Takahiro Tsushima, 2 Keisho Chin, 6 Akihisa Tomori, 7 … WebPhase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) Academic research paper on "Clinical medicine" 0. 0. Share paper. Academic journal. Cancer Science. 2014. OECD Field of science. Clinical medicine; Keywords {""}
WebWe conducted a phase I/II trial of adding 2‐weekly docetaxel to cisplatin plus fluorouracil therapy in esophageal cancer patients to investigate its and anti‐tumor activity. This … Web20 mag 2013 · e15016. Background: Thougha triplet chemotherapy with D plus CF (DCF) has shown promising activity, high incidence of adverse events (AEs) especially in febrile neutropenia (FN) was observed in previous studies for head and neck cancer (TAX323, 324) and gastric cancer (TAX325). To reduce its AEs with keeping activity, we conducted a …
WebPhase I⁄II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) Shuichi Hironaka,1 Yasuhiro Tsubosa, 2Junki … Web26 apr 2013 · Kenichi Nakamura, Ken Kato, Hiroyasu Igaki, Yoshinori Ito, Junki Mizusawa, Nobutoshi Ando, Harushi Udagawa, Yasuhiro Tsubosa, Hiroyuki Daiko, Shuichi …
WebNational Center for Biotechnology Information
Web2 feb 2015 · We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807). Promising efficacy and safety were shown in JCOG0807, and we have commenced a Phase III trial in September 2014 to confirm the superiority of 2-weekly DCF to CF for patients … magick store hollywoodWeb16 mag 2024 · Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, Tsushima T, Chin K, Tomori A, Okuno T, Taniki T, Ura T, Matsushita H, Kojima T, Doki Y, Kusaba H, Fujitani K, Taira K, Seki S, Nakamura T, Kitagawa Y ; Japan … magick supply shopsWeb17 set 2024 · JCOG0807 study revealed 2-weekly DCF regimen was less toxic and effective for unresectable or metastatic ESCC, however its efficacy for resectable ESCC as an induction chemotherapy is unknown. Methods. The aim of this study was to clarify the safety and efficacy of 2-weekly DCF regimen for resectable ESCC. magick tarot onlineWeb20 gen 2015 · 183 Background: ETS and DpR have been recognized as favorable prognostic factors of metastatic colorectal cancer. However, the effect of tumor shrinkage on clinical outcomes has not yet been reported for metastatic esophageal cancer (mEC). The purpose of the present study is to determine the associations of ETS and DpR with … nys hero act extendedWebPhase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Vice-President; Research output: Contribution to journal › Article › peer-review. 55 Citations (Scopus) magick stream lost arkWeb31 lug 2024 · SCP: 087: Directed by James Troici. With Mor Cohen, Jake Koropshinsky, Ronnie Toone. A mysterious staircase with no end, but with a few secrets for those who … magick supplies onlineWebuse of the JCOG0807 trial clinical data. Furthermore, the JCOG0807 trial is registered at the University Hospital Medical Information Network Clinical Trials Registry under the … magick subscription box